MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk

Dow Jones06-13

1320 ET - MBX Biosciences is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath's 64%. That said, the analysts believe some investors might argue that Yorvipath's real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide's once-weekly dosing schedule, which allows for 86% fewer injections and "continue to support canvuparatide's commercial potential," they say. (dean.seal@wsj.com)

(END) Dow Jones Newswires

June 12, 2026 13:21 ET (17:21 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643529266?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-13 01:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643529266","market":"us","top_or_hot":-1,"title":"MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1320 ET - <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a> is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath's 64%. That said, the analysts believe some investors might argue that Yorvipath's real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide's once-weekly dosing schedule, which allows for 86% fewer injections and \"continue to support canvuparatide's commercial potential,\" they say. (dean.seal@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2026 13:21 ET (17:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-13 01:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1320 ET - <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a> is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath's 64%. That said, the analysts believe some investors might argue that Yorvipath's real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide's once-weekly dosing schedule, which allows for 86% fewer injections and \"continue to support canvuparatide's commercial potential,\" they say. (dean.seal@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 12, 2026 13:21 ET (17:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643529266","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643529266","pubTimestamp":1781284860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Copyright (c) 2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ASND":"Ascendis Pharma A/S","BK4211":"区域性银行","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","MBX":"MBX Biosciences","ISBC":"投资者银行","BK4139":"生物科技"},"translate_title":"MBX的旗舰药物试验符合预期，但也许一些投资者想要更多——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"ASND":0.9,"MBX":1.5},"content_text":"1320 ET - MBX Biosciences is off 5.5% following results of a Phase 2 trial of its canvuparatide treatment for hypoparathyroidism. Mizuho says the drug achieved a 57% composite responder rate, a metric for treatment success, at 52 weeks, which is comparable to its competitor Yorvipath's 64%. That said, the analysts believe some investors might argue that Yorvipath's real benchmark rate is 80% under a more relaxed standard tied to patient use. But the analysts are still upbeat on the results and canvuparatide's once-weekly dosing schedule, which allows for 86% fewer injections and \"continue to support canvuparatide's commercial potential,\" they say. (dean.seal@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2026 13:21 ET (17:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643529266","isCrawlerRequest":true}